Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 30

Related Articles by Review for PubMed (Select 16371674)

1.

A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder.

Wigal SB, McGough JJ, McCracken JT, Biederman J, Spencer TJ, Posner KL, Wigal TL, Kollins SH, Clark TM, Mays DA, Zhang Y, Tulloch SJ.

J Atten Disord. 2005 Aug;9(1):275-89.

PMID:
16371674
2.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
3.

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

Gibson AP, Bettinger TL, Patel NC, Crismon ML.

Ann Pharmacother. 2006 Jun;40(6):1134-42. Epub 2006 May 30. Review.

PMID:
16735655
4.

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.

Findling RL.

Clin Ther. 2008 May;30(5):942-57. doi: 10.1016/j.clinthera.2008.05.006. Review.

PMID:
18555941
5.
6.

Stimulant therapy in the management of ADHD: mixed amphetamine salts (extended release).

Faraone SV.

Expert Opin Pharmacother. 2007 Sep;8(13):2127-34. Review.

PMID:
17714065
7.

Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder.

Brams M, Mao AR, Doyle RL.

Postgrad Med. 2008 Sep;120(3):69-88. doi: 10.3810/pgm.2008.09.1909. Review.

PMID:
18824827
8.

Adderall XR: long acting stimulant for single daily dosing.

Sallee FR, Smirnoff AV.

Expert Rev Neurother. 2004 Nov;4(6):927-34. Review.

PMID:
15853519
11.

An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.

Chavez B, Sopko MA Jr, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT.

Ann Pharmacother. 2009 Jun;43(6):1084-95. doi: 10.1345/aph.1L523. Epub 2009 May 26. Review.

PMID:
19470858
12.

Attention-deficit/hyperactivity disorder in adults: evidence-based recommendations for management.

Rostain AL.

Postgrad Med. 2008 Sep;120(3):27-38. doi: 10.3810/pgm.2008.09.1905. Review.

PMID:
18824823
13.

Update on drugs for hyperactivity in childhood.

[No authors listed]

Drug Ther Bull. 2007 May;45(5):37-40. Review. Erratum in: Drug Ther Bull. 2007 Nov;45(11):88. Drug Ther Bull. 2007 Aug;45(8):64.

PMID:
17536494
14.

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.

Health Technol Assess. 2006 Jul;10(23):iii-iv, xiii-146. Review.

15.

New options in the pharmacological management of attention-deficit/hyperactivity disorder.

Olfson M.

Am J Manag Care. 2004 Jul;10(4 Suppl):S117-24. Review.

16.

Attention-deficit-hyperactivity disorder: an update.

Dopheide JA, Pliszka SR.

Pharmacotherapy. 2009 Jun;29(6):656-79. doi: 10.1592/phco.29.6.656. Review.

PMID:
19476419
17.

Pharmacotherapy of adult ADHD.

Dodson WW.

J Clin Psychol. 2005 May;61(5):589-606. Review.

PMID:
15723384
18.

Current pharmacotherapy of attention deficit hyperactivity disorder.

Reddy DS.

Drugs Today (Barc). 2013 Oct;49(10):647-65. doi: 10.1358/dot.2013.49.10.2008996. Review.

PMID:
24191257
19.

Current strategies in the diagnosis and treatment of childhood attention-deficit/hyperactivity disorder.

Rader R, McCauley L, Callen EC.

Am Fam Physician. 2009 Apr 15;79(8):657-65. Review.

20.

Treatment of attention deficit hyperactivity disorder in adults.

Greenfield B, Hechman L.

Expert Rev Neurother. 2005 Jan;5(1):107-21. Review.

PMID:
15853481
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk